• Je něco špatně v tomto záznamu ?

AML-029 Quizartinib Prolonged Overall Survival (OS) vs Placebo Plus Intensive Induction and Consolidation Therapy Followed by Single-Agent Continuation in Patients Aged 18-75 Years With Newly Diagnosed FLT3-Internal Tandem Duplication Positive (FLT3-ITD+) Acute Myeloid Leukemia (AML)

H. Erba, P. Montesinos, R. Vrhovac, E. Patkowska, HJ. Kim, P. Zak, PN. Wang, T. Mitov, J. Hanyok, L. Liu, A. Benzohra, A. Lesegretain, J. Cortes, A. Perl, M. Sekeres, H. Dombret, S. Amadori, J. Wang, M. Levis, R. Schlenk

. 2022 ; 22 Suppl 2 (-) : S208-S209. [pub] -

Jazyk angličtina Země Spojené státy americké

Typ dokumentu klinické zkoušky, fáze III, časopisecké články, randomizované kontrolované studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc22024259

OBJECTIVES: Quizartinib is an oral, potent, selective, type II FLT3 inhibitor with prolonged OS as a single-agent in relapsed/refractory FLT3-ITD+ AML. We report results from the global, randomized, double-blind, phase 3 QuANTUM-First trial (NCT02668653), evaluating quizartinib plus standard induction and post-remission consolidation (including allogeneic hematopoietic cell transplant [allo-HCT] in first complete remission [CR1]) followed by single-agent continuation (up to 3 years) vs placebo plus chemotherapy in newly diagnosed FLT3-ITD+ AML. METHODS: Patients 18-75 years with newly diagnosed FLT3-ITD+ AML received induction with cytarabine 100 or 200 mg/m2/day (days 1-7) and daunorubicin 60 mg/m2/day or idarubicin 12 mg/m2/day (days 1-3). Patients were randomized to quizartinib (40 mg/day [days 8-21]) or placebo; stratified by region, age, and white blood cell count at diagnosis. Patients with CR or CR with incomplete hematologic recovery (CRi) received up to 4 cycles of high-dose cytarabine plus quizartinib (40 mg/day) or placebo and/or allo-HCT followed by continuation with quizartinib (30-60 mg/day) or placebo (up to 3 years). The primary endpoint was OS. RESULTS: Between September 2016 and August 2019, 539 patients were randomized (quizartinib [n=268], placebo [n=271]). Median age was 56 years (range, 20-75 years). As of August 2021 (median follow-up, 39.2 months), 58 patients remained on continuation. Median OS was significantly longer with quizartinib vs placebo (31.9 vs 15.1 months; HR, 0.776; 95% CI, 0.615-0.979; 2-sided P=.0324). CR+CRi rates were 71.6% and 64.9%, respectively. Allo-HCT in CR1 was performed in 157 patients (quizartinib, 31%; placebo, 27%). When censored for allo-HCT, OS trended longer with quizartinib vs placebo (HR, 0.752; 95% CI, 0.562-1.008; 2-sided P=.055). Relapse-free survival was longer with quizartinib vs placebo (HR, 0.733; 95% CI, 0.554-0.969). Grade ≥3 adverse events (AEs) were similar across arms. Discontinuations due to AEs occurred in 20.4% (quizartinib) and 8.6% (placebo). Fifty-six patients died from treatment-emergent AEs (quizartinib, 11.3%; placebo, 9.7%); mostly infections. Grade 3/4 electrocardiographic QT prolongation occurred in 3.0% (quizartinib) and 1.1% (placebo). CONCLUSIONS: Quizartinib plus standard therapy, followed by continuation, including after allo-HCT, for up to 3 years was tolerable with statistically significant and clinically meaningful OS improvements in adults ≤75 years with newly diagnosed FLT3-ITD+ AML.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22024259
003      
CZ-PrNML
005      
20240418103301.0
007      
ta
008      
221017s2022 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/S2152-2650(22)01212-5 $2 doi
035    __
$a (PubMed)36163755
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Erba, Harry $u Duke Cancer Institute, Durham, NC, USA
245    10
$a AML-029 Quizartinib Prolonged Overall Survival (OS) vs Placebo Plus Intensive Induction and Consolidation Therapy Followed by Single-Agent Continuation in Patients Aged 18-75 Years With Newly Diagnosed FLT3-Internal Tandem Duplication Positive (FLT3-ITD+) Acute Myeloid Leukemia (AML) / $c H. Erba, P. Montesinos, R. Vrhovac, E. Patkowska, HJ. Kim, P. Zak, PN. Wang, T. Mitov, J. Hanyok, L. Liu, A. Benzohra, A. Lesegretain, J. Cortes, A. Perl, M. Sekeres, H. Dombret, S. Amadori, J. Wang, M. Levis, R. Schlenk
520    9_
$a OBJECTIVES: Quizartinib is an oral, potent, selective, type II FLT3 inhibitor with prolonged OS as a single-agent in relapsed/refractory FLT3-ITD+ AML. We report results from the global, randomized, double-blind, phase 3 QuANTUM-First trial (NCT02668653), evaluating quizartinib plus standard induction and post-remission consolidation (including allogeneic hematopoietic cell transplant [allo-HCT] in first complete remission [CR1]) followed by single-agent continuation (up to 3 years) vs placebo plus chemotherapy in newly diagnosed FLT3-ITD+ AML. METHODS: Patients 18-75 years with newly diagnosed FLT3-ITD+ AML received induction with cytarabine 100 or 200 mg/m2/day (days 1-7) and daunorubicin 60 mg/m2/day or idarubicin 12 mg/m2/day (days 1-3). Patients were randomized to quizartinib (40 mg/day [days 8-21]) or placebo; stratified by region, age, and white blood cell count at diagnosis. Patients with CR or CR with incomplete hematologic recovery (CRi) received up to 4 cycles of high-dose cytarabine plus quizartinib (40 mg/day) or placebo and/or allo-HCT followed by continuation with quizartinib (30-60 mg/day) or placebo (up to 3 years). The primary endpoint was OS. RESULTS: Between September 2016 and August 2019, 539 patients were randomized (quizartinib [n=268], placebo [n=271]). Median age was 56 years (range, 20-75 years). As of August 2021 (median follow-up, 39.2 months), 58 patients remained on continuation. Median OS was significantly longer with quizartinib vs placebo (31.9 vs 15.1 months; HR, 0.776; 95% CI, 0.615-0.979; 2-sided P=.0324). CR+CRi rates were 71.6% and 64.9%, respectively. Allo-HCT in CR1 was performed in 157 patients (quizartinib, 31%; placebo, 27%). When censored for allo-HCT, OS trended longer with quizartinib vs placebo (HR, 0.752; 95% CI, 0.562-1.008; 2-sided P=.055). Relapse-free survival was longer with quizartinib vs placebo (HR, 0.733; 95% CI, 0.554-0.969). Grade ≥3 adverse events (AEs) were similar across arms. Discontinuations due to AEs occurred in 20.4% (quizartinib) and 8.6% (placebo). Fifty-six patients died from treatment-emergent AEs (quizartinib, 11.3%; placebo, 9.7%); mostly infections. Grade 3/4 electrocardiographic QT prolongation occurred in 3.0% (quizartinib) and 1.1% (placebo). CONCLUSIONS: Quizartinib plus standard therapy, followed by continuation, including after allo-HCT, for up to 3 years was tolerable with statistically significant and clinically meaningful OS improvements in adults ≤75 years with newly diagnosed FLT3-ITD+ AML.
650    _2
$a dospělí $7 D000328
650    _2
$a benzothiazoly $7 D052160
650    _2
$a chemoterapie konsolidační $7 D060830
650    _2
$a cytarabin $x terapeutické užití $7 D003561
650    _2
$a daunomycin $x terapeutické užití $7 D003630
650    12
$a transplantace hematopoetických kmenových buněk $x metody $7 D018380
650    _2
$a lidé $7 D006801
650    _2
$a idarubicin $x terapeutické užití $7 D015255
650    12
$a akutní myeloidní leukemie $x farmakoterapie $x genetika $7 D015470
650    _2
$a lidé středního věku $7 D008875
650    _2
$a fenylmočovinové sloučeniny $7 D010671
650    _2
$a tyrosinkinasa 3 podobná fms $x genetika $7 D051941
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
700    1_
$a Montesinos, Pau $u La Fe University and Polytechnic Hospital, Valencia, Spain
700    1_
$a Vrhovac, Radovan $u University Hospital Centre Zagreb, Zagreb, Croatia
700    1_
$a Patkowska, Elzbieta $u Institute of Hematology and Blood Transfusion, Warsaw, Poland
700    1_
$a Kim, Hee-Je $u The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Korea, Republic of
700    1_
$a Zak, Pavel $u University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
700    1_
$a Wang, Po-Nan $u Chang Gung Medical Foundation, Linkou, Taiwan
700    1_
$a Mitov, Tsvetomir $u Daiichi Sankyo UK Ltd, Uxbridge, United Kingdom
700    1_
$a Hanyok, James $u Daiichi Sankyo, Inc, Basking Ridge, NJ, USA
700    1_
$a Liu, Li $u Daiichi Sankyo, Inc, Basking Ridge, NJ, USA
700    1_
$a Benzohra, Aziz $u Daiichi Sankyo, Inc, Basking Ridge, NJ, USA
700    1_
$a Lesegretain, Arnaud $u Daiichi Sankyo, Inc, Basking Ridge, NJ, USA
700    1_
$a Cortes, Jorge $u Augusta University Medical Center, Augusta, GA, USA
700    1_
$a Perl, Alexander $u University of Pennsylvania, Philadelphia, PA, USA
700    1_
$a Sekeres, Mikkael $u Sylvester Cancer Center, University of Miami Health System, Miami, FL, USA
700    1_
$a Dombret, Hervé $u Saint Louis Hospital, University of Paris, Paris, France $7 xx0316388
700    1_
$a Amadori, Sergio $u Tor Vergata Polyclinic Hospital Rome, Rome, Italy
700    1_
$a Wang, Jianxiang $u Institute of Hematology and Blood Diseases Hospital, Tianjin, China
700    1_
$a Levis, Mark $u Johns Hopkins University, Baltimore, MD, USA
700    1_
$a Schlenk, Richard $u Heidelberg University Hospital and German Cancer Research Center, Heidelberg, Germany
773    0_
$w MED00180199 $t Clinical lymphoma, myeloma & leukemia $x 2152-2669 $g Roč. 22 Suppl 2 (2022), s. S208-S209
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36163755 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20221017 $b ABA008
991    __
$a 20240418103255 $b ABA008
999    __
$a ok $b bmc $g 1854148 $s 1175549
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 22 Suppl 2 $c - $d S208-S209 $e - $i 2152-2669 $m Clinical lymphoma, myeloma & leukemia $n Clin Lymphoma Myeloma Leuk $x MED00180199
LZP    __
$a Pubmed-20221017

Najít záznam

Citační ukazatele

Možnosti archivace